November 15-18, 2026 | San Antonio, TX | Booth #207

StageBio is heading to San Antonio for the American College of Toxicology's 47th Annual Meeting. ACT brings together toxicologists, pathologists, regulatory scientists, and drug developers to share the latest in safety assessment, nonclinical study design, and regulatory strategy, making it one of the most important gatherings of the year for teams advancing programs toward IND and beyond.

Our team will be on-site at Booth 207 throughout the meeting. Whether you're planning an IND-enabling tox package, navigating unexpected findings in an ongoing study, or looking for a pathology partner who can scale with your pipeline, we'd love to connect. 

Toxicologic Pathology Built for Regulatory Confidence

Safety assessment lives and dies on the quality of the tissue-level data behind it. At StageBio, toxicologic pathology isn't a single step in the process; it's the core of what we do. From necropsy through regulatory submission, we deliver GLP-compliant pathology data that sponsors and regulators can trust.

•  GLP Toxicologic Pathology: A team of 20+ board-certified veterinary pathologists provides histopathologic evaluation across all major preclinical species, supporting general toxicology, repeat-dose, and IND-enabling studies with study design input, reporting, and pathology peer review.

• End-to-End Laboratory Support: Necropsy, histology, imaging, and archiving under one roof, supported by 100+ trained lab professionals across our sites in Frederick, MD; Maurertown, VA; and Freiburg, Germany.

• Specialized Histology & Biomarkers: Advanced capabilities including IHC/IF assay development and custom biomarker validation help clarify mechanism and characterize findings when standard endpoints aren't enough.

• Modality Expertise: Experience across small molecules, biologics, cell and gene therapies, and medical devices, so your study is evaluated by pathologists who understand the safety considerations specific to your platform.

• Regulatory-Ready Deliverables: Reports, peer reviews, and SEND-ready data packages designed to support submissions and keep programs on schedule.

Early pathology input can shape dose selection, safety margins, and study design before costly surprises arise. Stop by Booth 207 to talk through your next study with our team.

Meet Our Team

	David Bruning CEO David Bruning is Chief Executive Officer of StageBio, leading the company’s global strategy and operations across North America and Europe. With more than 25 years of experience in the pharmaceutical and biotechnology industries, and prior service as a StageBio board member and customer, he brings deep insight into client needs and preclinical services. His focus is on advancing scientific rigor, service quality, and StageBio’s role as a trusted histopathology partner.
	Joy Gary, DVM, PhD, DACVP Senior Pathologist, Neuropathology Dr. Joy Gary is a board-certified veterinary pathologist at StageBio, where she provides specialized neuropathology evaluations to support the preclinical development of neuroactive compounds and biomolecules. Her expertise spans neuropathology, toxicologic pathology, digital pathology, and animal models of disease, with additional experience in immunohistochemistry and in situ hybridization method development. Dr. Gary is a strong advocate for the vital role of the pathologist in biomedical research.
	Ailsa Delgado Director, Account Manager & Client Services Ailsa Delgado is a Director of Account Management and Client Services at StageBio with more than 18 years of experience fostering strategic partnerships across pharmaceutical, biotech, government, and academic organizations. She takes a deeply customer-centric approach to supporting non-clinical and clinical programs, working closely with clients to align goals, study needs, and expertise, driving long-term collaboration and successful program outcomes.
	Yasmine Shakibi Business Development Executive Yasmine Shakibi is a Business Development Executive at StageBio, supporting biotech and research organizations. With a background in histology and pathology CRO services, she works closely with discovery and translational teams to clarify needs, align timelines, and connect clients with the right scientific expertise. Her collaborative, tech-enabled approach helps fast-moving teams move programs forward efficiently.
	Beth Saba Account Manager Beth Saba is an Account Manager at StageBio with more than 15 years of experience building solution-oriented partnerships with biotech, pharmaceutical, and CRO clients. She brings a deep understanding of the scientific, operational, and compliance priorities behind preclinical and translational programs, including GLP and ISO standards. Beth works closely with clients to align complex research needs with targeted solutions, helping programs move forward efficiently, reliably, and within budget.

Connect With Us in San Antonio

Visit StageBio at Booth 207 during ACT 2026, November 15-18, to discuss your toxicologic pathology needs, explore partnership opportunities, or simply say hello.

Can't wait until the meeting? Book a call with our scientific team to start the conversation early.

For more information about StageBio's preclinical and clinical pathology services, visit www.stagebio.com.